Therapie des metastasierten Prostatakarzinoms im Wandel – neue Daten und offene Fragen
Author:
Publisher
Springer Science and Business Media LLC
Subject
Urology
Link
http://link.springer.com/content/pdf/10.1007/s00120-019-01072-0.pdf
Reference52 articles.
1. Almeida DVP, de Oliviera CZ, Mariano RC et al (2018) Non-metastatic castration-resistant prostate cancer: meta-analysis of efficacy and safety with hormonal agents apalutumide and enzalutamide. Ann Oncol 29(suppl_8):viii271–viii302. https://doi.org/10.1093/annonc/mdy284
2. Angelergues A, Maillet D, Flechon A et al (2014) Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 32(suppl 4):282a
3. Angelergues A, Efstathiou E, Gyftaki R et al (2018) Results of the FLAC European database of metastatic castration-resistant prostate cancer patients treated with docetaxel, cabazitaxel, and androgen receptor-targeted agents. Clin Genitourin Cancer 16(4):e777–e784
4. Attard G, Borre M, Gurney H et al (2018) Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment. J Clin Oncol 36(25):2639–2646
5. Boevé LMS, Hulshof MCCM, Vis AN et al (2018) Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol. https://doi.org/10.1016/j.eururo.2018.09.008
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Current Trends in Advanced Prostate Cancer Medical Setting;Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.;2022-04-01
2. CARD-Studie – Bedeutung für die Therapie des fortgeschrittenen Prostatakarzinoms;Aktuelle Urologie;2020-09-23
3. Behandlung des Primärtumors beim oligometastasierten Prostatakarzinom;Aktuelle Urologie;2020-05-05
4. Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings;Critical Reviews in Oncology/Hematology;2020-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3